Literature DB >> 21599567

Perindopril for the treatment of hypertension.

Lorenzo Ghiadoni1.   

Abstract

INTRODUCTION: Treatment of hypertension is fundamental for the prevention of cardiovascular events and mortality. This review focuses on the specific benefits of the ACE inhibitor perindopril. AREAS COVERED: A systematic literature search is undertaken for supporting the pharmacological proprieties and clinical efficacy of perindopril in the treatment of hypertension. Good tissue penetration, strong affinity for ACE and a long duration of action support the dose-dependent blood pressure lowering efficacy. Perindopril in combination with amlodipine significantly reduced total and cardiovascular mortality as compared to atenolol/diuretic in large-scale clinical trials of hypertensive patients. A greater reduction in blood pressure variability, central blood pressure and specific vascular protective proprieties of perindopril (improvement in arterial stiffness and endothelial function) might explain these results. Cardiovascular prevention with perindopril, in combination with indapamide, has been also shown in the elderly and patients with diabetes, cardio- and cerebrovascular diseases. EXPERT OPINION: Perindopril is effective and safe for blood pressure control with a dose-dependent effect. Combination therapy with indapamide or amlodipine reduces cardiovascular events and mortality in hypertensive patients. Pharmacological proprieties and results of clinical trials support the choice of perindopril as an appropriate treatment for hypertensive patients.
© 2011 Informa UK, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21599567     DOI: 10.1517/14656566.2011.585460

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  1 in total

1.  Efficacy and Safety of Perindopril in Patients with Essential Hypertension.

Authors:  Enisa Hodzic; Ehlimana Pecar; Alen Dzubur; Elnur Smajic; Zorica Hondo; Daniela Delic; Edhem Rustempasic
Journal:  Mater Sociomed       Date:  2020-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.